anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Current research has shown evidence that phytocannabinoids may have a promising therapeutic potential in a variety of physical and psychological ailments, and cannabidiol (CBD) is of particular interest due to its positive safety profile, non-intoxicating effects and widespread capabilities in a number of musculoskeletal diseases. Three primary reasons people consume CBD on a global basis, in addition to the fact that it is non-intoxicating, are for symptomatic (pain) relief, anxiety reduction, and improved sleep quality. Very little is known about CBD and how it functions in the body from both an efficacy and mechanistic perspective, especially in humans. There is a large consumer base for this product that will be expanding exponentially in the next few years. Most of the evidence available is anecdotal from the personal testimony of consumers. We aim to determine the efficacy of a controlled short-term trial of CBD ingestion for reducing symptomatic response and facilitating recovery following induced muscle injury. In addition, we aim to identify if the effects are dose-dependent by utilizing a low-dose (25 mg/day), high-dose (62.5 mg/day) and vehicle-control (0 mg/day) ingestion regimen. We will assess, in serial fashion, symptomatic response, functional limitations and recovery of the quadriceps muscle following induced injury in which selected doses of CBD oil will be administered orally during a 15-day pre-injury consumption and post-injury recovery phase. A double-blind, randomized, three-arm study design will be used and participants will be randomly assigned to either a high dose (n=15), low dose (n=15), or vehicle control group (n=15). Our clinical outcomes include measures of muscular pain and disability along with measures of pain-related fear and anxiety. Our laboratory-based study design is desirable and advantageous because it is a controlled method of tracking individuals using an experimental model of injury that is translatable to clinical populations. Another advantage of this study design is that it will address, in parallel fashion, two of the primary reasons people are consuming CBD - symptomatic relief and anxiety reduction. This exploratory study will provide preliminary data needed to support the hypotheses of a planned larger scale application.
Huntington Disease (HD) is a progressive neurological condition, eventually leading to death. Presymptomatic, predictive genetic testing can inform individuals of their genetic status. A positive genetic test result can be a threatening event. In adapting to threatening events people often try and find meaning in the experience. Meaning making refers to the attempt to understand an event or experience and its significance in the context of one's life. The search for meaning can eventually lead to acceptance of an event or experience, and is considered an important component of adaptation. Although it has been established that testing for HD can be a significantly stressful event, and that meaning making is a frequent response towards adaptation, little is known about this process among individuals faced with a positive genetic test result for HD. This study will describe meaning making in a population of presymptomatic individuals with a positive genetic test result for HD.

Semi-structured interviews will be conducted, recorded, transcribed, and analyzed. A typology of common themes will be compiled and reported. Data gathered from these interviews will improve understanding of the phenomenon of meaning making in this population, and will contribute to the existing literature on the role of meaning making in cognitive adaptation. This study will specifically help gain insight into the process of meaning making among individuals who have tested positive for HD, and may potentially inform the ways in which health care professionals can help facilitate meaning-making among this population, in their process of adaptation to a stressful live event.
PURPOSE:To provide a hair restorer having excellent hair grow accelerating effect, containing a specific porphyrin compound. CONSTITUTION:Hair tonic, hair cream, etc. containing 0.1-3.0% of a porphyrin compound of formula (R is OH, Cl), i.e. hematin (R is OH) or hemin (R is Cl). The compound, which can be prepared from animal blood (e.g. cattle, pig, etc.), reacts with melanoside existing in the hair bulb tissue, accelerates the activation of catalase, and promotes the hair growing. Since the compound has an activity to activate tyrosinase and catalase which are enzymes affecting the production of melanin, is effective to restore black hair.
The present invention relates to the technical field of medicines, more specifically an antitumor compound Philinopside E separated from pentacta quadrangulasis, and the molecular formula of the antitumor compound Philinopside E is C53H81O24NaS. The chemical structure and the spatial configuration of the compound are determined by multiple kinds of modern spectrum analysis, particularly by the application of multiple kinds of advanced two-dimensional NMR spectroscopy comprehensive analysis. The antitumor experiment in vitro indicates that the compound has obvious suppression action on nine kinds of tumor cell strains such as HL-6 human leukemia, P-388 mouse leucoma, etc. The antitumor experiment in vivo indicates that the compound has obvious tumor inhibiting effect on mouse S180 sarcoma and mouse H22 liver cancer. The antitumor experiment for inhibiting tumor neovascularization indicates that the compound has obvious inhibiting effect on tumor neovascularization. The present invention provides a lead compound for developing new antitumor medicines and has important value to develop and utilize Chinese ocean medicinal biological resources.
<P>PROBLEM TO BE SOLVED: To provide a polypeptide which is an HLA class II binding WT1 antigen peptide.  <P>SOLUTION: The polypeptide for achieving the object is derived from WT1, i.e. an HLA class II binding WT1 antigen peptide composed of a specific amino acid sequence. A WT1-specific CD4<SP>+</SP>T cell activated by the polypeptide recognizes a polypeptide bound to an HLA class II molecule on a leukemia cell and directly develops HLA class II bound cytotoxicity to the leukemia cell. The polypeptide is useful in the field of immunotherapy such as cellular immunotherapy, vaccinotherapy and gene therapy on malignant tumors including leukemia.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Air pollution is one of the leading causes of early deaths worldwide, with particulate matter (PM) as an emerging factor contributing to this trend. PM is classified based on its physical size, which ranges from PM10 (diameter ≤10 μm) to PM2.5 (≤2.5 μm) and PM0.5 (≤0.5 μm). Smaller-sized PM can move freely through the air and readily infiltrate deep into the lungs, intensifying existing health issues and exacerbating complications. Lung complications are the most common issues arising from PM exposure due to the primary site of deposition in the respiratory system. Conditions such as asthma, COPD, idiopathic pulmonary fibrosis, lung cancer and various lung infections are all susceptible to worsening due to PM exposure. PM can epigenetically modify specific target sites, further complicating its impact on these conditions. Understanding these epigenetic mechanisms holds promise for addressing these complications in cases of PM exposure. This involves studying the effect of PM on different gene expressions and regulation through epigenetic modifications, including DNA methylation, histone modifications and microRNAs. Targeting and manipulating these epigenetic modifications and their mechanisms could be promising strategies for future treatments of lung complications. This review mainly focuses on different epigenetic modifications due to PM2.5 exposure in the various lung complications mentioned above.
More than 700.000 open abdominal surgeries (laparotomies) are performed each year in Germany (2). A major surgical complication after laparotomy is abdominal fascia dehiscence which might appear either as early (burst abdomen with evisceration) or as late complication (incisional hernia). These patients usually undergo surgery for secondary fascial closure associated with markedly increased morbidity (3) including high recurrence rates (up to 45%) (4). The applied surgical strategy of abdominal wall closure (i.e. the combination of suture technique and material) is of high relevance for prevention of fascia dehiscence and, moreover, constitutes the main factor directly controllable by the surgeon. While several randomized controlled trials (RCT) (3; 5-8) as well as meta-analyses (9-12) exist that address the issue of optimal fascia closure in elective laparotomies, there is no RCT dealing exclusively with the emergency setting. As a result abdominal fascia closure is performed according to the surgeon's individual preference rather than according to evidence-based data. Therefore, the present RCT is designed to compare the most established strategies (continuous slowly absorbable sutures and interrupted rapidly absorbable sutures) for abdominal wall closure in order to determine differences between both strategies after midline incisions.
When plants are entirely submerged, photosynthesis and respiration are severely restricted, affecting plant growth and potentially even causing plant death. The AP2/ERF superfamily has been widely reported to play a vital role in plant growth, development and resistance to biotic and abiotic stresses. However, no relevant studies exist on flooding stress in pecan. In this investigation, we observed that CiAP2/ERF65 positively modulated the hypoxia response during submergence, whereas CiAP2/ERF106 was sensitive to submergence. The levels of physiological and biochemical indicators, such as POD, CAT and among others, in CiAP2/ERF65-OE lines were significantly higher than those in wild-type Arabidopsis thaliana, indicating that the antioxidant capacity of CiAP2/ERF65-OE lines was enhanced under submergence. The RNA-seq results revealed that the maintenance of the expression levels of the antenna protein gene, different signaling pathways for regulation, as well as the storage and consumption of ATP, might account for the opposite phenotypes of CiAP2/ERF65 and CiAP2/ERF106. Furthermore, the expression of some stress-related genes was altered during submergence and reoxygenation. Overall, these findings enhance our understanding of submergence stress in pecan, providing important candidate genes for the molecular design and breeding of hypoxia resistant in plants.
Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1.Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with placebo alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued.
Abnormal uterine bleeding is the most common gynecologic complaint in reproductive aged women. Medical treatment of abnormal uterine bleeding has high failure rates and surgical management remains the primary, definitive therapy. Most women undergoing hysterectomy for abnormal bleeding failed a therapeutic trial of medical management. Consequently, development of an efficacious, new medical treatment for abnormal uterine bleeding is urgently needed. Many of these reproductive aged women also need contraception. Ulipristal acetate (UPA), a novel progesterone receptor modulator developed at the NIH, has promise as an effective medical treatment for abnormal uterine bleeding and as a contraceptive agent. In women with symptomatic fibroids, UPA significantly reduced fibroid size, stopped menstrual bleeding and led to an increase in red blood cell hemoglobin. It also inhibited release of an egg from the ovaries (ovulation) without reducing estrogen levels or causing hot flashes, making contraception a potential future use.

This study will evaluate UPA effects on estrogen production and ovulation, and will determine whether it reduces bleeding in women who have abnormal uterine bleeding as assessed by the Menorrhagia Impact Questionnaire (MIQ) and menstrual calendars. Women with an anatomic abnormality of the uterus are not eligible to participate. Participants will take UPA (10 mg daily by mouth) or a similar-appearing inactive pill (placebo) for approximately 90 days. Women will be randomly assigned to receive daily UPA 10 mg, or a daily placebo tablet, during the initial three-month period. The participants and the investigators will not be informed of the treatment group. To understand the effects of UPA on the uterus and its lining (endometrium), women will have studies before and at the end of UPA treatment, including ultrasound imaging of the uterus after injection of a small amount of sterile saline into the uterine cavity, and a biopsy of the endometrium to examine the tissue under the microscope. Before and while taking study agent, women will record daily bleeding and complete the MIQ monthly. During the treatment period, blood will be taken weekly to measure hormone levels (to evaluate ovulation blockage), and monthly to evaluate safety. At the end of the randomized study period, the research team will offer participants additional options of UPA or surgical therapy. Women may choose surgical therapy at the NIH or may elect other treatment options elsewhere.
Oxaliplatin 85 mg/m² over 3 hours at Day 1 and Day 15. 5-FU 2,000 mg/m² over 4 hours at Day 1. Folinic acid 20 mg/m² Bolus at Day 1.
<P>PROBLEM TO BE SOLVED: To provide a method for producing carpophores of insect parasite fungus, which enables rapid and stable production of carpophores of insect parasite fungi.  <P>SOLUTION: The method for producing carpophores of insect parasite fungi comprises scratching the epidermis of an insect, inoculating the insect parasite fungi into a scratched part to increase the insect parasite fungi in the body of the insect so that the carpophores of the insect parasite fungi are formed. The insect parasite fungi uses for example Cordyceps sinensis (Berkeley) Saccardo fungi, the insects uses lepidopteran such as Spodoptera litura. It is preferable to culture the insect parasite fungi on an agar medium or a grain medium to form fungal hyphae of the insect parasite fungi on the medium, and place the insect having the scratch on its epidermis on the fungal hyphae to inoculate the insect parasite fungi to the insect. The insect parasite fungi grow proliferously in the body of the insect to harden the insect so as to form carpophores primordia on its epidermis as spawns to produce the carpophores.  <P>COPYRIGHT: (C)2007,JPO&INPIT
In some aspects, described herein are improved enhancer elements, effective fragments thereof, and their use in vectors. In some aspects, described herein is a minimal backbone enhancer element structure, and its use in vectors. In some aspects, described herein is expression of a gene product (e.g., WAS protein) using such improved enhancer elements, for example, in a vector having the described minimal backbone enhancer element structure. In some aspects, the vectors described herein are lentiviral vectors. In some aspects, the described enhancer elements, minimal backbone enhancer element structure and vectors lead to improved gene transfer, viral titer, expression of the gene product encoded by the vector, and/or improved biological or clinical effects. Also described herein are uses of such enhancer elements, minimal backbone enhancer element structure and vectors for the treatment of diseases, for example for the treatment of diseases associated with deficient WASp expression such as Wiskott-Aldrich Syndrome (WAS).
PURPOSE: To analyze the clinicopathological characteristics and surgical outcomes of patients with Wolfring gland ductal cysts (WGDCs).
METHODS: A retrospective, consecutive, interventional comparative case series was performed over a period of 7 years. Data on demographic and clinical characteristics, pathological findings and outcomes of surgically excised cysts were collected. A comparison between the transconjunctival and transcutaneous approaches was also assessed.
RESULTS: Forty-eight patients (48 eyelids) were included in the final analysis. The most common presenting symptom was painless eyelid swelling (81.3%). The median symptom duration was 11.5 months (IQR, 18.25). The upper eyelid was involved in 31 (64.6%) patients, 29/31 of whom had cysts in a medial or centromedial location. Forty-five (93.8%) cysts were bluish gray and transilluminable with clear contents on lid eversion and a median largest dimension of 22 mm (IQR, 8). A transverse conjunctival fibrotic band was observed along the proximal tarsal border in the cyst area in all patients. Signs of chronic trachoma were noted in 38 (79.2%) patients. Preoperative significant ptosis was present in 28/31 (90.3%) of the upper eyelid cysts. Thirty cysts (62.5%) were excised through the skin, and 18 cysts (37.5%) were excised transconjunctivally. Intraoperative cyst rupture, the need for conjunctival grafting and postoperative residual upper lid ptosis were significantly greater in the transconjunctival group (p = 0.009, p < 0.001, and p = 0.016, respectively).
CONCLUSION: The present study highlights the clinicopathological characteristics of a relatively large series of surgically excised WGDCs. Transcutaneous excision of WGDCs has proven to be an effective treatment with fewer adverse sequelae than the transconjunctival approach.
The present invention relates to a training system using a neurofeedback device and image content for improvement of a developmental disorder function, and a training method thereof. The training system of the present invention comprises: the neurofeedback device; an image processing device; a display device; and a database. The neurofeedback device measures trainee's brain wave information in real time. The image processing device collects and analyzes the measured brain wave information from the neurofeedback device, and sets a compensated brain wave, a suppressed brain wave, and a threshold value according to a brain development state of the trainee. The image processing device selects and plays or executes image content suitable for the trainee's age according to the set brain wave information and displays the image content on the display device of the trainee. The image processing device runs repeated training sessions so as to improve the trainee's neurodevelopmental disorder function by real-time measuring, collecting, and analyzing the brain wave information in which the trainee responds to the displayed image content. According to the present invention, it is possible to improve the neurodevelopmental disorder function in many people with developmental disorders having various symptoms by processing logical thinking and function training together with physical brain function training using the neurofeedback device and various kinds of image content.
2 groups of physiotherapists with different fields of experience were attended to study. Fingers are positioned on the marked area at the center point of the scale. Therapists were asked to apply pressure to the scale with estimated weights of 0.5 kg, 1 kg, 2 kg and 4 kg. In each measurements, the value on the scale was recorded without being shown to the participants. After the measurements, the participants were made to experiment when the digital screen can be seen, in order to teach the physiotherapists how much pressure they applied to reach the target weight. Participants were given a total of 10 minutes for the trials. Then, the digital screen was hidden again, and the therapist was asked to apply 0.5 kg, 1 kg, 2 kg and 4 kg weight in a randomized order and maintain that pressure for 5 seconds. The weight fixed by the therapist for 5 seconds was noted by the researcher; the participant was not informed about the values on the digital screen.
The physician who prescribes epinephrine auto-injector should review this Prescribing Information insert in detail with the patient. This review should include the proper use of epinephrine auto-injector to ensure that subcutaneous or intramuscular injections are given into the anterolateral aspect of the thigh, through clothing if necessary. The accompanying Patient Information Leaflet and Wrap Label should also be reviewed with the patient.

Epinephrine auto-injector is capable of delivering one dose of either 0.15 mg or 0.3 mg (0.15 mL or 0.3 mL of epinephrine). This dose is available for auto-injection by the patient.

Selection of the appropriate epinephrine auto-injector dosage strength is determined according to patient body weight.

The usual dose of epinephrine for allergic emergencies in patients who weigh 30 kilograms or greater is 0.3 mg (0.3 mL of epinephrine).

Since the doses of epinephrine delivered from epinephrine auto-injector are fixed, the physician should consider other forms of injectable epinephrine if doses lower than those available from epinephrine auto-injector are felt to be necessary. The prescribing physician should carefully assess each patient to determine the most appropriate dose of epinephrine, recognizing the life-threatening nature of the reactions for which this drug is being prescribed.

Patients should be instructed to periodically visually inspect the epinephrine solution for particulate matter and discoloration. If the solution contains particulate matter or develops a pinkish color or becomes darker than slightly yellow, the patient should immediately contact their physician for a replacement, since these changes indicate that the effectiveness of the drug product may be decreased.
Patients randomized to treatment arm 2, will start treatment with Optune GIO® for 3-10 days and receive one infusion of pembrolizumab before undergoing MLA/biopsy. Patients will resume Optune GIO® no earlier than 10 days post-surgery and receive pembrolizumab 200 mg IV every 3 weeks (+/- 4 days) starting no sooner than 1 week after the start of Optune GIO®.
Subjects with retinal dystrophy will have their visual field, gait and self-reported mobility tested at baseline. Subjects will then be fit with a head-mounted display and undergo a brief training with the investigators to learn about use of the device. After a 2 week period of in-home adaptation to the device, their visual field, gait and self-reported mobility will be retested.
This group will attend to seven days pelvic floor muscle strengthening programme with moderate intensity consisting of 6 exercises recommended by the national association for incontinence. Prior to discharge exercise sheets will be given to the participants. Their compliance to exercise will be questioned with daily phone calls.
Systems, methods, computer-readable media, and apparatuses for identifying and executing one or more interactive condition evaluation tests to generate an output are provided. In some examples, user information may be received by a system and one or more interactive condition evaluation tests may be identified. An instruction may be transmitted to a computing device of a user and executed on the computing device to enable functionality of one or more sensors that may be used in the identified tests. A user interface may be generated including instructions for executing the identified tests. Upon initiating a test, data may be collected from one or more sensors in the computing device. The data collected may be transmitted to the system and may be processed using one or more machine learning datasets to generate an output.